-
Something wrong with this record ?
Computational Prodrug Design Methodology for Liposome Formulability Enhancement of Small-Molecule APIs
M. Balouch, K. Storchmannová, F. Štěpánek, K. Berka
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Fluorouracil MeSH
- Lipid Bilayers chemistry MeSH
- Liposomes * chemistry MeSH
- Permeability MeSH
- Prodrugs * chemistry MeSH
- Tissue Distribution MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Encapsulation into liposomes is a formulation strategy that can improve efficacy and reduce side effects of active pharmaceutical ingredients (APIs) that exhibit poor biodistribution or pharmacokinetics when administered alone. However, many APIs are unsuitable for liposomal formulations intended for parenteral administration due to their inherent physicochemical properties─lipid bilayer permeability and water-lipid equilibrium partitioning coefficient. Too high permeability results in premature leakage from liposomes, while too low permeability means the API is not able to pass across biological barriers. There are several options for solving this issue: (i) change of the lipid bilayer composition, (ii) addition of a permeability enhancer, or (iii) modification of the chemical structure of the API to design a prodrug. The latter approach was taken in the present work, and the effect of small changes in the molecular structure of the API on its permeation rate across a lipidic bilayer was systematically explored utilizing computer simulations. An in silico methodology for prodrug design based on the COSMOperm approach has been proposed and applied to four APIs (abiraterone, cytarabine, 5-fluorouracil, and paliperidone). It is shown that the addition of aliphatic hydrocarbon chains via ester or amide bonds can render the molecule more lipophilic and increase its permeability by approximately 1 order of magnitude for each 2 carbon atoms added, while the formation of fructose adducts can provide a more hydrophilic character to the molecule and reduce its lipid partitioning. While partitioning was found to depend only on the size and type of the added group, permeability was found to depend also on the added group location. Overall, it has been shown that both permeability and lipid partitioning coefficient can be systematically shifted into the desired liposome formulability window by appropriate group contributions to the parental drug. This can significantly increase the portfolio of APIs for which liposome or lipid nanoparticle formulations become feasible.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010503
- 003
- CZ-PrNML
- 005
- 20230801132451.0
- 007
- ta
- 008
- 230718s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.molpharmaceut.2c01078 $2 doi
- 035 __
- $a (PubMed)36939094
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Balouch, Martin $u Department of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 3, 166 28 Prague 6, Czech Republic
- 245 10
- $a Computational Prodrug Design Methodology for Liposome Formulability Enhancement of Small-Molecule APIs / $c M. Balouch, K. Storchmannová, F. Štěpánek, K. Berka
- 520 9_
- $a Encapsulation into liposomes is a formulation strategy that can improve efficacy and reduce side effects of active pharmaceutical ingredients (APIs) that exhibit poor biodistribution or pharmacokinetics when administered alone. However, many APIs are unsuitable for liposomal formulations intended for parenteral administration due to their inherent physicochemical properties─lipid bilayer permeability and water-lipid equilibrium partitioning coefficient. Too high permeability results in premature leakage from liposomes, while too low permeability means the API is not able to pass across biological barriers. There are several options for solving this issue: (i) change of the lipid bilayer composition, (ii) addition of a permeability enhancer, or (iii) modification of the chemical structure of the API to design a prodrug. The latter approach was taken in the present work, and the effect of small changes in the molecular structure of the API on its permeation rate across a lipidic bilayer was systematically explored utilizing computer simulations. An in silico methodology for prodrug design based on the COSMOperm approach has been proposed and applied to four APIs (abiraterone, cytarabine, 5-fluorouracil, and paliperidone). It is shown that the addition of aliphatic hydrocarbon chains via ester or amide bonds can render the molecule more lipophilic and increase its permeability by approximately 1 order of magnitude for each 2 carbon atoms added, while the formation of fructose adducts can provide a more hydrophilic character to the molecule and reduce its lipid partitioning. While partitioning was found to depend only on the size and type of the added group, permeability was found to depend also on the added group location. Overall, it has been shown that both permeability and lipid partitioning coefficient can be systematically shifted into the desired liposome formulability window by appropriate group contributions to the parental drug. This can significantly increase the portfolio of APIs for which liposome or lipid nanoparticle formulations become feasible.
- 650 12
- $a liposomy $x chemie $7 D008081
- 650 12
- $a prekurzory léčiv $x chemie $7 D011355
- 650 _2
- $a tkáňová distribuce $7 D014018
- 650 _2
- $a lipidové dvojvrstvy $x chemie $7 D008051
- 650 _2
- $a fluoruracil $7 D005472
- 650 _2
- $a permeabilita $7 D010539
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Storchmannová, Kateřina $u Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 12, 771 46 Olomouc, Czech Republic
- 700 1_
- $a Štěpánek, František $u Department of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 3, 166 28 Prague 6, Czech Republic $1 https://orcid.org/0000000192884568 $7 mzk2012703367
- 700 1_
- $a Berka, Karel $u Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 12, 771 46 Olomouc, Czech Republic $1 https://orcid.org/0000000194722589 $7 ola2015878473
- 773 0_
- $w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 20, č. 4 (2023), s. 2119-2127
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36939094 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132448 $b ABA008
- 999 __
- $a ok $b bmc $g 1963118 $s 1196768
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 20 $c 4 $d 2119-2127 $e 20230320 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
- LZP __
- $a Pubmed-20230718